tetano
Editor, Senior Moderator
Clin Exp Nephrol
. 2022 Jun 25.
doi: 10.1007/s10157-022-02243-8. Online ahead of print.
SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan
Daisuke Kanai[SUP] #[/SUP][SUP] 1 [/SUP], Hiromichi Wakui[SUP] #[/SUP][SUP] 1 [/SUP], Tatsuya Haze[SUP] #[/SUP][SUP] 2 [/SUP], Kengo Azushima[SUP] 1 [/SUP], Sho Kinguchi[SUP] 1 [/SUP], Shunichiro Tsukamoto[SUP] 1 [/SUP], Tomohiko Kanaoka[SUP] 1 [/SUP], Shingo Urate[SUP] 1 [/SUP], Yoshiyuki Toya[SUP] 1 [/SUP], Nobuhito Hirawa[SUP] 3 [/SUP], Hideaki Kato[SUP] 4 [/SUP], Fumimasa Watanabe[SUP] 5 [/SUP], Kanako Hanaoka[SUP] 5 [/SUP], Masaaki Hanaoka[SUP] 5 [/SUP], Hiroshi Mitsuhashi[SUP] 5 [/SUP], Satoshi Yamaguchi[SUP] 6 [/SUP], Toshimasa Ohnishi[SUP] 5 [/SUP], Kouichi Tamura[SUP] 7 [/SUP]
Affiliations
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is shown to prevent severe illness and death in hemodialysis (HD) patients, but the immune response to vaccines is reduced in this population. This study compared SARS-CoV-2 spike protein antibody titers between HD patients and healthy controls in Japan for up to 6 months following vaccination.
Methods: A multi-institutional retrospective study at five clinics in Japan was conducted using 412 HD patients and 156 healthy controls who received two doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. Anti-SARS-CoV-2 spike protein S1 IgG antibody titers were measured at 1, 3, and 6 months after the second dose. The attenuation speed was calculated as slope (i.e., -β) using a linear mixed-effects model toward the log-transformed antibody titers.
Results: The HD group had significantly lower month 1 antibody titers (Ab-titer-1) than the controls, and these remained lower through month 6 (95% CI: 2617.1 (1296.7, 5240.8) vs. 7285.4 (4403.9, 11,000.0) AU/mL at Ab-titer-1, and 353.4 (178.4, 656.3) vs. 812.0 (498.3, 1342.7) AU/mL at Ab-titer-6 (p < 0.001, respectively)). Lower log Ab-titer-1 levels in the HD group were significantly associated with a lower log Ab-titer-6 (0.90 [0.83, 0.97], p < 0.001). The -β values in the HD patients and healthy controls were -4.7 ± 1.1 and -4.7 ± 1.4 (year[SUP]-1[/SUP]), respectively.
Conclusion: SARS-CoV-2 spike protein antibody titers were significantly lower in HD patients than in healthy controls at 1 (peak) and 6 months after the second vaccination. Low peak antibody titers contributed to low 6-month antibody titers.
Keywords: Antibody; BNT162b2; Hemodialysis; SARS-CoV-2; vaccine.
. 2022 Jun 25.
doi: 10.1007/s10157-022-02243-8. Online ahead of print.
SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan
Daisuke Kanai[SUP] #[/SUP][SUP] 1 [/SUP], Hiromichi Wakui[SUP] #[/SUP][SUP] 1 [/SUP], Tatsuya Haze[SUP] #[/SUP][SUP] 2 [/SUP], Kengo Azushima[SUP] 1 [/SUP], Sho Kinguchi[SUP] 1 [/SUP], Shunichiro Tsukamoto[SUP] 1 [/SUP], Tomohiko Kanaoka[SUP] 1 [/SUP], Shingo Urate[SUP] 1 [/SUP], Yoshiyuki Toya[SUP] 1 [/SUP], Nobuhito Hirawa[SUP] 3 [/SUP], Hideaki Kato[SUP] 4 [/SUP], Fumimasa Watanabe[SUP] 5 [/SUP], Kanako Hanaoka[SUP] 5 [/SUP], Masaaki Hanaoka[SUP] 5 [/SUP], Hiroshi Mitsuhashi[SUP] 5 [/SUP], Satoshi Yamaguchi[SUP] 6 [/SUP], Toshimasa Ohnishi[SUP] 5 [/SUP], Kouichi Tamura[SUP] 7 [/SUP]
Affiliations
- PMID: 35751753
- DOI: 10.1007/s10157-022-02243-8
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is shown to prevent severe illness and death in hemodialysis (HD) patients, but the immune response to vaccines is reduced in this population. This study compared SARS-CoV-2 spike protein antibody titers between HD patients and healthy controls in Japan for up to 6 months following vaccination.
Methods: A multi-institutional retrospective study at five clinics in Japan was conducted using 412 HD patients and 156 healthy controls who received two doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. Anti-SARS-CoV-2 spike protein S1 IgG antibody titers were measured at 1, 3, and 6 months after the second dose. The attenuation speed was calculated as slope (i.e., -β) using a linear mixed-effects model toward the log-transformed antibody titers.
Results: The HD group had significantly lower month 1 antibody titers (Ab-titer-1) than the controls, and these remained lower through month 6 (95% CI: 2617.1 (1296.7, 5240.8) vs. 7285.4 (4403.9, 11,000.0) AU/mL at Ab-titer-1, and 353.4 (178.4, 656.3) vs. 812.0 (498.3, 1342.7) AU/mL at Ab-titer-6 (p < 0.001, respectively)). Lower log Ab-titer-1 levels in the HD group were significantly associated with a lower log Ab-titer-6 (0.90 [0.83, 0.97], p < 0.001). The -β values in the HD patients and healthy controls were -4.7 ± 1.1 and -4.7 ± 1.4 (year[SUP]-1[/SUP]), respectively.
Conclusion: SARS-CoV-2 spike protein antibody titers were significantly lower in HD patients than in healthy controls at 1 (peak) and 6 months after the second vaccination. Low peak antibody titers contributed to low 6-month antibody titers.
Keywords: Antibody; BNT162b2; Hemodialysis; SARS-CoV-2; vaccine.